Myeloma Patients Europe

01/03/2026

March is

We're dedicating this month to raising awareness and sharing patient experiences and insights.

Join us each Friday as we share inspiring stories of people living well with myeloma.

28/02/2026

Today is .

A global campaign which aims to represent the under-represented. The campaign unites over 70 national partners across 100 countries to raise awareness and drive policy change for the estimated 300 million people living with a rare disease worldwide.

Did you know nearly one in five cancers is classified as a rare disease?

The day is coordinated by -Rare Diseases Europe https://f.mtr.cool/eqmrmbplxh"

26/02/2026

Can we define a cure for myeloma?

Clinical experts met last weekend at the Myeloma Cure Summit to discuss this question, organised by the International Myeloma Society.

Read MPE's highlight's from the cure summit here
https://f.mtr.cool/oacjkwoyig

25/02/2026

Myeloma treatment can feel overwhelming; your breath can be an anchor.

Try this: breathe in slowly for four counts, hold for four, breathe out for four, hold for four. Repeat five times! Simple breathing exercises can reduce anxiety, lower heart rate, and give you a moment of calming reflection on those difficult days.

24/02/2026

Personalised treatment based on fitness? Can we better tailor myeloma treatment according to a patient's level of fitness and frailty?

Dr. Charlotte Pawlyn discusses the UK MRA FiTNESS trial, which evaluates whether the International Myeloma Working Group frailty score can guide treatment decisions for better outcomes.

https://f.mtr.cool/vrdoopolhj

The UK MRA FiTNEss trial aims to understand whether the International Myeloma Working Group (IMWG) frailty score can be used to tailor treatment according to...

23/02/2026

Myeloma patients — Share your treatment experience, help shape the future of myeloma care

Patient insights are essential to help us shape research, policy and care across Europe. We'd love to hear from you, so we can find out what is important to you.

If you've been treated with any of the following, please consider joining one of our focus groups:
🔹 Bispecific antibodies (teclistamab, elranatamab)
🔹 CAR T-cell therapy (cilta-cel, ide-cel)
🔹 Antibody–drug conjugates (belantamab mafodotin)
🔹 Selinexor (nexpovio®)

Please register your interest or to help, share within your own networks.

Please register your interest or share within your own networks.-https://www.mpeurope.org/share-your-experience-with-bispecific-antibodies-car-t-cell-therapy-and-antibody-drug-conjugates/

23/02/2026

Searching for clinical trials doesn't have to be confusing. Our short video walks you through how to use the Myeloma and AL Amyloidosis Clinical Trial Navigator step by step. https://f.mtr.cool/yvocpjqvon

In just a few minutes, you'll learn how to search for trials.

20/02/2026

Congratulations to Claudia Bellofiore, Paolo Milani and all co-authors for their newly published paper in HemaSphere: Eligibility criteria for clinical trials in AL amyloidosis result in exclusion of nearly half of real-world patients.

This research shines a light on a critical issue in clinical trial access — findings that have real implications for patients living with AL amyloidosis across Europe and beyond.

Read the full article here 👉 https://f.mtr.cool/ystdyjdewv

18/02/2026

You don't have to face myeloma or AL amyloidosis alone. Myeloma Patients Europe works with 52 member organisations across 33 countries to ensure patients and carers have access to support, information and a community.

Whether you need information about myeloma, emotional support from others who understand your experience, or help navigating your healthcare system, our member organisations are here for you.

Connect with support in your country and find the resources you need. Our member organisations offer local expertise, language-specific information, and peer support networks, all while advocating for better care.

Find your local organisation https://f.mtr.cool/mehxrptjyj

17/02/2026

Simplifying first-line treatment: The LINKER-MM4 trial investigates linvoseltamab as a simplified monotherapy option for newly diagnosed myeloma patients.
Speaking at Dr. Xavier Leleu explains the safety and efficacy findings from this approach to frontline treatment.

Dr. Xavier Leleu, Centre Hospitalier Universitaire de Poitiers, France, explains the main results of the LINKER-MM4 clinical trial which evaluates safety and...

16/02/2026

Looking for clinical trials for myeloma, MGUS, smouldering myeloma, or AL amyloidosis in Europe? Our Clinical Trial Navigator makes it simple.

This free online tool helps patients, carers, and advocates search for trials in a patient-friendly way. You can discover what trials are available, where they're located, and what they involve - all in one place.
We created this navigator because finding clinical trials shouldn't be complicated. Whether you're exploring treatment options or want to contribute to research, this tool gives you the information you need.

Learn more
https://f.mtr.cool/hshvakupip

Visit
https://f.mtr.cool/tjsxnccnts

16/02/2026

Saturday was the last day of the EBMT- Hematology Association (EHA) 8th European CAR T-cell Meeting!

It was an excellent conference where basic science and innovation met clinical practice. Despite manufacturing and access challenges, researchers are working together to develop cheaper, safer and more efficient CAR-T therapies. Treatment resistance and relapse were extensively discussed, with growing interest in innovative approaches such as in vivo CAR-Ts – where T-cells are modified directly in the body rather than in a laboratory – and dual-targeting CAR-Ts, which attack cancer cells in two different ways simultaneously, instead of the single-target approach of currently authorised therapies.

The nurses' track addressed important topics, including fertility preservation, survivorship, cognitive impairments following CAR-T treatment, and emerging care challenges.

We look forward to next year's edition, which will be held from 4–6 February in Lisbon, Portugal!